Paediatric Diseases Working Party (PDWP)
Type d'étude:
Numéro de l'étude:
8417020
Type de traitement à base de cellules souches:
Maladies:
Titre court:
Objectif principal:
Primary objective is to determine the effectivity of eculizumab treatment in HSCT-TMA in children.The goal is to collect the unpublished real-life experience of eculizumab use that may help the current practice and shape the future research.
Principaux critères d'inclusion:
- Age 0-18yrs
- Allogeneic haematopoietic stem cell transplantation recipient
- HSCT-TMA diagnosed according to any of the 6 criteria listed (defined in the questionnaire, attached))
- Treatment with eculizumab
- Informed consent given for EBMT registry data collection
- Allogeneic haematopoietic stem cell transplantation recipient
- HSCT-TMA diagnosed according to any of the 6 criteria listed (defined in the questionnaire, attached))
- Treatment with eculizumab
- Informed consent given for EBMT registry data collection
Pays:
Investigateur principal:
Peter Svec
Coordinateur EBMT de l'étude:
Arnaud Dalissier